Product
10E8.4/iMab
2 clinical trials
1 indication
Indication
HIV-1 infectionClinical trial
Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure ProphylaxisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Bispecific Antibody 10E8.4/iMab in HIV-1-infected and Uninfected IndividualsStatus: Completed, Estimated PCD: 2022-03-23